| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer |
NCT01654263: A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine |
|
|
| Completed | 2b | 884 | US | Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] | National Institute of Allergy and Infectious Diseases (NIAID) | Pneumococcal Infection | 08/15 | 08/15 | | |
NCT01229176: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants |
|
|
| Completed | 2a | 200 | RoW | Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Typherix, Pneumococcal conjugate vaccine, Prevenar 13 | Novartis | Typhoid Fever | 06/12 | 06/12 | | |
| Completed | 2 | 480 | Canada, Europe | GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™, Menjugate®, Rotarix™ | GlaxoSmithKline | Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis, Acellular Pertussis, Diphtheria, Neisseria Meningitidis | 10/11 | 10/11 | | |
| Completed | 2 | 721 | Europe, RoW | Infanrix hexa™, DTPa-HBV-IPV/Hib, Prevenar 13®, Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine, GSK217744 | GlaxoSmithKline | Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria | 01/12 | 01/12 | | |
| Completed | 2 | 1152 | NA | V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13® | Merck Sharp & Dohme LLC | Pneumococcal Infections | 07/12 | 07/12 | | |
NCT01437267: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants |
|
|
| Completed | 2 | 120 | RoW | Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Prevenar 13, Vi Polysaccharide (PS) vaccine, Typherix | Novartis | Typhoid Fever | 08/12 | 08/12 | | |
NCT01513551 / 2011-004542-18: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) |
|
|
| Completed | 2 | 692 | NA | Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13® | Merck Sharp & Dohme LLC | Pneumococcal Infections | 02/13 | 02/13 | | |
NCT02547649: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) |
|
|
| Completed | 2 | 690 | NA | V114-A, V114-B, Prevnar 13® | Merck Sharp & Dohme LLC | Pneumococcal Infections | 01/16 | 01/16 | | |
NCT00205803: Study Evaluating Pneumococcal Vaccine in Healthy Infants |
|
|
| Completed | 1/2 | 249 | US | 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC) | Wyeth is now a wholly owned subsidiary of Pfizer | Healthy Subjects, Pneumococcal Infections | | 05/07 | | |
NCT02531373: A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) |
|
|
| Completed | 1/2 | 338 | NA | V114 Medium Dose, V114 High Dose, V114 Medium Dose with Alternative Carrier Protein, V114 High Dose with Alternative Carrier Protein, Prevnar 13™ | Merck Sharp & Dohme LLC | Pneumococcal Infections | 04/17 | 04/17 | | |
